Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity

As the one-year anniversary of Bristol-Myers Squibb Company’s $74bn acquisition of Celgene Corporation approaches, Scrip spoke with chief medical officer Samit Hirawat about the big pharma’s achievements during a challenging period in which the COVID-19 pandemic threatened to derail clinical trials and a national spotlight on racial inequality shined a light on the industry’s lack of diversity.